Tag: Verona Pharma (VRNA)

Prohost Letter #461 ~ Preventing HIV Infection and Treating Primary Biliary Cholangitis

Prohost Letter #461 Preventing HIV Infection and Treating Primary Biliary Cholangitis Gilead Sciences Gilead Sciences’ (GILD) stock price has been paralyzed for more than three consecutive years.  The long paralysis of Gilead reminds us of Amgen Therapeutics whose stock price was paralyzed at $50 for more than 3 years. The stock rebounded and continued to outperform after we selected it in 2011 Recently, Gilead announced …

Verona Pharma Announces the US FDA Approval of Ohtuvayre™ for the Maintenance Treatment of COPD

Verona Pharma in the NEWS Yesterday, June 26, 2024, Verona Pharma plc (VRNA) announced that the US FDA has approved Ohtuvayre (ensifentrine) for maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients. Ohtuvayre is the first inhaled product with a novel mechanism of action available for the maintenance treatment of COPD in more than 20 years. The product . . . This content …

Current News From Three Selected Biotech Firms

Three Biotech Firm in the NEWS Verona Pharma Verona Pharma plc (VRNA) announced that senior management will present a company overview at the following conferences in November 2023: Jefferies London Healthcare Conference Date: Wednesday, November 15, 2023 Time: 10:00 AM EST / 3:00 PM GMTLocation: London, UK Piper Sandler 35th Annual Healthcare . . . This content is for paid subscribers. Please click here to subscribe or …